BioCentury
ARTICLE | Product Development

LTIZ warning on Amphocil

January 3, 1995 8:00 AM UTC

Liposome Technology Inc. has sent a letter to doctors in the U.K. advising them of adverse reactions in 21 patients taking Amphocil liposomal amphotericin B for systemic fungal infections. The Menlo Park, Calif., company recommended slowing the rate of infusion for patients receiving high doses who show the reaction.

"The reaction is self-limiting if you slow the infusion," said CFO Peter Leigh. Patients can also be treated with antihistamines and steroids. ...